摘要
目的探究麝香保心丸联合沙库巴曲缬沙坦应用于老年冠心病患者经皮冠状动脉介入(percutaneous coronary intervention,PCI)术后的疗效及对患者心室重构的影响。方法选取2019年1月至2022年9月上饶市立医院收治的60例老年冠心病PCI术后患者作为研究对象,按照随机数字表法分为观察组与对照组,每组30例。对照组采用沙库巴曲缬沙治疗,观察组采用麝香保心丸联合沙库巴曲缬沙坦治疗。比较两组临床疗效、心室重构指标[左心室舒张末期内径(left ventricular end-diastolic diameter,LVEDD)、左心室收缩末期内径(left ventricular end-systolic dimension,LVESD)、左心室射血分数(left ventricular ejection fraction,LVEF)、左心室质量指数(left ventricular mass index,LVMI)]、血清指标[N-末端脑钠肽前体(N-terminal pro-B-type natriuretic peptide,NT-proBNP)、甘油三酯、总胆固醇]及不良心血管事件发生情况。结果治疗3、6个月,两组LVESD、LVEDD均短于前一时间点,LVEF均高于前一时间点,LVMI均低于前一时间点,且观察组LVESD、LVEDD均短于对照组,LVEF高于对照组,LVMI低于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率为96.67%,高于对照组的80.00%,差异有统计学意义(P<0.05)。治疗3、6个月,两组NT-proBNP水平均低于前一时间点,甘油三酯均低于治疗前,治疗6个月后,两组总胆固醇水平均低于治疗前、治疗3个月,差异有统计学意义(P<0.05);治疗3、6个月,观察组NT-proBNP水平低于对照组,差异有统计学意义(P<0.05);两组甘油三酯、总胆固醇水平比较差异无统计学意义。两组不良心血管事件发生率比较差异无统计学意义。结论麝香保心丸联合沙库巴曲缬沙坦应用于老年冠心病患者PCI术后疗效显著,可显著改善患者术后心功能,预防患者心室重构,减少心血管不良事件的发生。
Objective To explore the effect of Shexiang Baoxin pills combined with sacubitril valsartan on postoperative efficacy and ventricular remodeling in elderly patients with coronary heart disease after percutaneous coronary intervention(PCI).Methods 60 elderly patients with coronary heart disease after PCI admitted to Shangrao Municipal Hospital from January 2019 to September 2022 were selected as the research subjects,they were divided into the observation group and the control group according to the random number table method,with 30 cases in each group.The control group was treated with sacubitril valsartan,and the observation group was treated with Shexiang Baoxin pills combined with sacubitril valsartan.The control group was treated with sacubitril valsartan,and the observation group was treated with Shexiang Baoxin pills combined with sacubitril valsartan.The clinical efficacy,ventricular remodeling indexes(left ventricular end-diastolic diameter[LVEDD],left ventricular end-systolic dimension[LVESD],left ventricular ejection fraction[LVEF],left ventricular mass index[LVMI]),serum indexes(N-terminal pro-B-type natriuretic peptide[NT-proBNP],triglyceride,total cholesterol)and adverse cardiovascular events were compared between the two groups.Results After 3 and 6 months of treatment,LVESD and LVEDD of the two groups were shorter than those at the previous time point,LVEF was higher than that at the previous time point,LVMI was lower than that at the previous time point,LVESD and LVEDD in the observation group were shorter than those in the control group,LVEF was higher than that in the control group,LVMI was lower than that in the control group,and the differences were statistically significant(P<0.05).The total effective rate of treatment in the observation group was 96.67%,which was higher than 80.00%in the control group,and the difference was statistically significant(P<0.05).After 3 and 6 months of treatment,NT-proBNP level of the two groups were lower than those at the previous time point,and triglyceride level was lower than that before treatment,after 6 months of treatment,total cholesterol level of the two groups was lower than that before treatment and after 3 months of treatment,and the differences were statistically significant(P<0.05);after 3 and 6 months of treatment,NT-proBNP level in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05);there were no significant differences in triglyceride and total cholesterol levels between the two groups.There was no significant difference in the incidence of adverse cardiovascular events between the two groups.Conclusion The curative effect of Shexiang Baoxin pills combined with sacubitril valsartan in elderly patients with coronary heart disease after PCI is significant,which can significantly improve the postoperative cardiac function,prevent ventricular remodeling and reduce the occurrence of cardiovascular adverse events.
作者
陈翔
吴新富
程永熙
邓筱琴
徐进
苏盛辉
CHEN Xiang;WU Xinfu;CHENG Yongxi;DENG Xiaoqin;XU Jin;SU Shenghui(Department of Cardiovascular Medicine,Shangrao Municipal Hospital,Shangrao,Jiangxi,334000,China)
出处
《当代医学》
2024年第36期63-68,共6页
Contemporary Medicine
基金
江西省卫生健康委科技计划(202312336)。
关键词
麝香保心丸
沙库巴曲缬沙坦
老年冠心病
心室重构
不良心血管事件
Shexiang Baoxin pills
Sacubitril valsartan
Elderly patients with coronary heart disease
Ventricular remodeling
Adverse cardiovascular events
